ALK e6::e20

CI-VAR-00004961Explore in graph →CIViC 503

Curated evidence

Evidence by cancer (8 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–8 of 8 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma7
EML4::ALK e6::e20	2,4-pyrimidinediamine	Predictive	D	Supports Sensitivity Response	4	accepted	EID1192 In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of E… (full text at CIViC) PMID 18593892 · Choi et al., 2008 · Open in CIViC	civic
EML4::ALK e6::e20	ALK Inhibitor TAE684	Predictive	D	Supports Sensitivity Response	2	accepted	EID1194 In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon… (full text at CIViC) PMID 18451166 · McDermott et al., 2008 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm1
EML4::ALK e6::e20	Crizotinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1245 This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm. Morphology and immunohistochemistry were unable to establish the primary tumor site. Right upper e… (full text at CIViC) PMID 25408655 · Chung et al., 2014 · Open in CIViC	civic